Drugs / FMP2.1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00358332 | Nov 2006 → Dec 2007 | Plasmodium falciparum malaria | U.S. Army Medical Research and Development Command | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02044198 Comparator | Mar → Dec 2014 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FMP2.1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02044198 ↗ |
| Known as | FMP2.1/AS02(A) | “The malaria vaccine FMP2.1/AS02(A) is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant...” PMID 20140214 ↗ Feb 2010 |
| Modality | Protein / enzyme biologic | “The malaria vaccine FMP2.1/AS02(A) is a recombinant protein (FMP2.1) based on apical membrane antigen 1 (AMA1) from the 3D7 clone of P. falciparum, formulated in the Adjuvant...” PMID 20140214 ↗ Feb 2010 |
| Route | Intramuscular | “administered by intramuscular injection” NCT00358332 ↗ |